Special Issues

Special Issue Title: BRCA and ovarian cancer

· Print Special Issue Flyer

· Deadline for manuscript submissions:  30 April 2021

Special Issue Editor

Guest Editor

              Prof. Dr. Gennaro Cormio

              University of Bari, Italy

Website | E-Mail

Interests: Vulvar cancer, Ovarian cancer

Special Issue Information

Dear Colleagues,

Ovarian cancer is the fifth cause of cancer death in women worldrwide. The role of BRCA 1-1 genes mutation ha resulted in a significant improvement in scientific research in this field. Brca mutation has been reported in about 15 to 30 % of ovarian cancer patients in different geographic areas. It has a probably a prognostic role but particularly a fundamental predictive role of response to PARP inhibitors and may be also other compounds. A number of researches are actually ongoing in order to confirm the potential role of this mutation in surgical and medical management of ovarian cancer. Moreover the role of BRCA gene mutation detection in the general population is fundamental in order to achieve a potential genetic prevention of ovarian cancer. A number of potential strategies are studied also concerning reproductive medicine and BRCA 1-2 mutation. The aim of this special issue of the Journal is to collect new insights on this fascinating topic.

Prof. Dr. Gennaro Cormio

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. We normally offer a discount greater than 30% (APC: $850) to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.


BRCA 1-2 mutation; Ovarian cancer; Prophylactic surgery; Reproductive medicine; Hormonal treatment

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
New treatment strategy for ovarian cancer with a BRCA gene mutation
Tadahiro Shoji, Kotoka Kikuchi, Hayato Kogita, Nanako Jonai, Hidetoshi Tomabechi, Akiko Kudoh, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba
European Journal of Gynaecological Oncology    2021, 42 (1): 1-9.   DOI: 10.31083/j.ejgo.2021.01.2251
Abstract333)   HTML64)    PDF(pc) (335KB)(230)       Save

Mutated BRCA1/2 genes have been identified as causative genes for ovarian cancer, and it has been reported that 10–20% of all epithelial ovarian cancers have a BRCA mutation. As novel treatment drugs utilizing this BRCA gene mutation, significant attention has been paid to adenine dinucleotide poly (ADP-ribose) polymerase inhibitors. Among them, olaparib has been reported to be useful in patients with a BRCA mutation in Study 19 and SOLO-2 trials. It is important to establish a system for genetic counseling and to perform BRCA gene testing in patients with ovarian cancer. For patients with BRCA -mutated advanced cancer, if adequate response to chemotherapy has been achieved, olaparib is recommended as maintenance therapy for both advanced and recurrent cases. For patients without BRCA gene mutation, bevacizumab combined with chemotherapy or as maintenance therapy is also an option.
Related Articles | Metrics

Current Issue

  • Volume 42, Issue 2